5

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: February 10, 2017
Period of Report: December 31, 2016
Accession Number: 0001237899-17-000014

View Document ↗ View on SEC.gov ↗